Compare Synektik SA with Similar Stocks
Dashboard
1
Strong Long Term Fundamental Strength with a 69.14% CAGR growth in Operating Profits
- The company is Net-Debt Free
- The company has been able to generate a Return on Capital Employed (avg) of 81.43% signifying high profitability per unit of total capital (equity and debt)
2
Flat results in Dec 25
3
With ROE of 52.29%, it has a attractive valuation with a 9.94 Price to Book Value
4
Consistent Returns over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
PLN 2,491 Million (Mid Cap)
19.00
NA
3.68%
-0.58
52.29%
9.64
Revenue and Profits:
Net Sales:
228 Million
(Quarterly Results - Dec 2025)
Net Profit:
43 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
42.0%
0%
42.0%
6 Months
63.76%
0%
63.76%
1 Year
105.62%
0%
105.62%
2 Years
224.01%
0%
224.01%
3 Years
756.6%
0%
756.6%
4 Years
1405.9%
0%
1405.9%
5 Years
1359.17%
0%
1359.17%
Synektik SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
42.10%
EBIT Growth (5y)
69.14%
EBIT to Interest (avg)
19.18
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.82
Sales to Capital Employed (avg)
3.12
Tax Ratio
20.17%
Dividend Payout Ratio
89.72%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
81.43%
ROE (avg)
23.83%
Valuation key factors
Factor
Value
P/E Ratio
19
Industry P/E
Price to Book Value
9.94
EV to EBIT
14.20
EV to EBITDA
12.59
EV to Capital Employed
22.26
EV to Sales
3.42
PEG Ratio
0.28
Dividend Yield
3.57%
ROCE (Latest)
156.76%
ROE (Latest)
52.29%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Bullish
Bullish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
228.00
199.20
14.46%
Operating Profit (PBDIT) excl Other Income
60.00
54.50
10.09%
Interest
1.80
0.80
125.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
43.10
39.40
9.39%
Operating Profit Margin (Excl OI)
236.90%
247.10%
-1.02%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 14.46% vs 29.18% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 9.39% vs 29.18% in Sep 2025
Annual Results Snapshot (Consolidated) - Sep'25
Sep'25
Sep'24
Change(%)
Net Sales
681.30
624.10
9.17%
Operating Profit (PBDIT) excl Other Income
178.30
123.70
44.14%
Interest
3.10
1.40
121.43%
Exceptional Items
0.00
-1.30
100.00%
Consolidate Net Profit
125.20
82.60
51.57%
Operating Profit Margin (Excl OI)
231.40%
171.80%
5.96%
USD in Million.
Net Sales
YoY Growth in year ended Sep 2025 is 9.17% vs 39.65% in Sep 2024
Consolidated Net Profit
YoY Growth in year ended Sep 2025 is 51.57% vs 57.33% in Sep 2024
About Synektik SA 
Synektik SA
Pharmaceuticals & Biotechnology
Synektik SA is a Poland-based company active in the medical sector. It produces PACS software which allows running a diagnostic imaging laboratory. It runs a research laboratory which performs acceptance and specialist tests of X-ray equipment. The Company sells medical equipment and operates a services center for imaging equipment. Synektik SA is a partner of Siemens. On November 28, 2013, the Company raised its stake in Miedzynarodowe Centra Medyczne Inwestycje Sp z o o to 100%.
Company Coordinates 
Company Details
Al. Witosa 31 , WARSZAWA None : 00-710
Registrar Details






